CSL overall growth 25-30% in FY27
Management expects the US subsidiary (CSL) to grow 25-30% in the coming year, driven by existing products and new launches.
CAPLINPOINTLABORATORIES / guidance tracker
Keep management guidance in view.
Caplin Point Laboratories · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Own-label revenue target ~₹200 crore in FY27
Aim to double own-label revenue from ~₹100 crore to ~₹200 crore in the next fiscal year.
Capex of ~₹500 crore over next 18-24 months
Remaining capex of about ₹500 crore to be spent on injectable plant phase 3, oral solids/derma facility, and oncology API plant.
17 injectable lines in 2-3 years
Company plans to have 17 injectable lines for US and regulated markets, with most machines imported from Germany and Italy.